I

Instituto Dante Pazzanese de Cardiologia | Divisão de Pesquisa

Research site

(Unclaimed)

Location

Avenue Doctor Dante Pazzanese, number 500 8º andar da torre, Sao Paulo, Sao Paulo, Brazil

Site insights

Top conditions

Top treatments

Warfarin

Apixaban

Olpasiran

Milvexian

Rosuvastatin

Sildenafil

Dabigatran

Mavacamten

Creatine

Tadalafil

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 28 total trials

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM)

The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic...

Active, not recruiting

Cardiomyopathy, Hypertrophic

Drug: Mavacamten

Other: Placebo

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling

Acute Coronary Syndrome

Drug: Milvexian

Other: Placebo

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling

Atrial Fibrillation

Drug: Apixaban Placebo

Drug: Milvexian

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Olpasiran

Drug: Placebo